Representing Kansas bioscience companies and research institutions
Home About KansasBio Membership Center Bioscience News Contact KansasBio
Information Resources Education & Training Networking & Collaboration Business & Investment

 

Up-to-the minute latest news in the biotechnology sector and from biotech companies in Kansas and around the world

  KansasBio photos  

Search:
 

Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012

 

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Chief Commercial Officer Scott Byrd will present the company's corporate overview on Tuesday, May 8, 2012 at 4:50pm Eastern Time (1:50pm Pacific Time) during the Deutsche Bank Securities, Inc. 37th Annual Health Care Conference at the Intercontinental Boston Hotel in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com, under "Events and Presentations." 

Contacts:

William R. LaRue


SVP, CFO


Cadence Pharmaceuticals, Inc.


858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.cadencepharm.com

 



Kansas Bioscience Association

© 2004 Kansas Bioscience Organization (KansasBio). All rights reserved.